Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New eye drop cocktail aims to quench dry eye Sufferers' tears

NCT ID NCT07128628

Symptom relief Sponsor: Bausch & Lomb Incorporated Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jul 15, 2026 · Updated 2 times

Summary

This Phase 2 trial tests a new eye drop that combines two active ingredients—lifitegrast and perfluorohexyloctane—for people with dry eye disease. About 423 adults will use the drops twice daily for 4 weeks. Researchers will measure changes in eye surface staining and symptom scores to see if the combo works better than either ingredient alone or a placebo.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Lifitegrast and perfluorohexyloctane eye drops
What this could lead to
If it works, this could offer a more effective twice-daily eye drop for dry eye symptoms like stinging and blurred vision.
What could go wrong
This is an early Phase 2 trial with only 4 weeks of treatment, so long-term benefits are unknown. The new combo may not work better than existing drops.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

443 people

The number who actually took part.

Started

Oct 2025

Finished

May 2026

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: This study will include subjects who meet all of the following inclusion criteria: * Voluntarily provide written informed consent * ≥18 years of age * Subject-reported history of DED OU for at least 6 months * Same eye satisfies the criteria for dry eye signs at both screening and baseline/randomization * The criteria for dry eye symptoms are met at both screening and baseline/randomization * As needed (PRN) or scheduled use of non-prescription (OTC) artificial tear, gels, or lubricants for symptoms of dry eye within the past 30 days * Able and willing to follow instructions, including participation in all trial assessments and visits Exclusion Criteria: This study will exclude subjects who meet any of the following exclusion criteria (Note: Ocular exclusion criteria are relevant to both eyes, such that meeting a criterion in either eye excludes the subject from the study): * Known allergy or sensitivity to any study treatment (or any of its components) * Best-corrected visual acuity (BCVA) of 0.7 logarithm of the minimum angle of resolution (logMAR) or worse (50 Early Treatment Diabetic Retinopathy Study \[ETDRS\] letters; Snellen equivalent score of 20/100 or worse) at Visit 1 (Screening) or Visit 2 (baseline/randomization) * Any clinically significant (CS) ocular surface slit-lamp findings at Visit 1 (Screening) or Visit 2 (baseline/randomization), or findings that may interfere with trial parameters in the opinion of the Investigator. * Use of any of any ocular therapies within 30 days. * Unable or unwilling to stop current topical dry eye treatments Additional criteria per protocol

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Dry eye disease are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

dry eye syndrome

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Dry eye disease

Contacts and locations

Locations

  • Advancing Vision Research, LLC

    Smyrna, Tennessee, 37167, United States

  • Asheville Eye Associates

    Asheville, North Carolina, 28803, United States

  • Bowden Eye and Associates

    Jacksonville, Florida, 32256, United States

  • CORE Inc.

    Shelby, North Carolina, 28150, United States

  • Clayton Eye Clinical Research, LLC

    Morrow, Georgia, 30260, United States

  • Complete Eye Care of Medina

    Medina, Minnesota, 55340, United States

  • Comprehensive Eye Care Ltd.

    Washington, Missouri, 63090, United States

  • Eye Doctors of Arizona, PLLC

    Phoenix, Arizona, 85028, United States

  • Eye Research Foundation, Inc.

    Newport Beach, California, 92663, United States

  • Global Research Management, Inc.

    Glendale, California, 91204, United States

  • Insight Eyecare Specialties, Inc.

    Kansas City, Missouri, 64111, United States

  • Insight Research Clinic LLC.

    Powell, Ohio, 43065, United States

  • Intouch Clinical Research Center

    Houston, Texas, 77034, United States

  • Kannarr Eye Care, LLC

    Pittsburg, Kansas, 66762, United States

  • Lake Travis Eye and Laser Center

    Lakeway, Texas, 78738, United States

  • LoBue Laser and Eye Medical Center

    Murrieta, California, 92562, United States

  • Midwest Cornea Associates LLC

    Carmel, Indiana, 46032, United States

  • Moyes Eye Center, P.C.

    Kansas City, Missouri, 64154, United States

  • Oculus Research

    Garner, North Carolina, 27529, United States

  • Ophthalmology Consultants, Ltd.

    St Louis, Missouri, 63131, United States

  • Opthalmic consultants of Long Island

    Garden City, New York, 11530, United States

  • Rochester Ophthalmological Group,PC

    Rochester, New York, 14618, United States

  • Scott & Christie Eyecare Associates - The Surgery Center at Cranberry

    Cranberry Township, Pennsylvania, 16066, United States

  • Segal Drug Trials/Office of Bruce A Segal, MD

    Delray Beach, Florida, 33484, United States

  • Shettle Eye Research, Inc

    Largo, Florida, 33773, United States

  • SoCal Eye - Lakewood Clinic

    Long Beach, California, 90805, United States

  • Southern College of Optometry

    Memphis, Tennessee, 38104, United States

  • Total Eye Care PA

    Memphis, Tennessee, 38119, United States

  • Vance Thompson Vision - Alexandria

    Alexandria, Minnesota, 56308, United States

  • Vance Thompson Vision - Fargo, ND

    West Fargo, North Dakota, 58078, United States

  • West Bay Eye Associates

    Warwick, Rhode Island, 02888, United States

  • Wolstan and Goldberg Eye Associates

    Torrance, California, 90505, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.